Becton Dickinson Collaborates with Ypsomed on New Syringe
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 23 2024
0mins
Should l Buy BDX?
Becton Dickinson and Co (BDX) has hit a 5-day low amid a broader market trend where the Nasdaq-100 is up 0.25% and the S&P 500 is up 0.01%.
The company recently announced a collaboration with Ypsomed to develop a 5.5mL syringe aimed at enhancing self-administration efficiency for patients. This product innovation is expected to meet the growing demand for large-volume subcutaneous injections, featuring an 8mm short needle and thinner wall cannulas to improve injection times and optimize flow. The partnership is poised to drive market growth in high-dose biopharmaceuticals, with syringe samples expected by mid-2026.
This collaboration highlights BDX's commitment to addressing patient needs in the high-dose biologics space, potentially positioning the company favorably in a competitive market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BDX
Wall Street analysts forecast BDX stock price to rise
11 Analyst Rating
5 Buy
6 Hold
0 Sell
Moderate Buy
Current: 154.510
Low
157.00
Averages
192.64
High
232.00
Current: 154.510
Low
157.00
Averages
192.64
High
232.00
About BDX
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. It operates through four segments: BD Medical Essentials, BD Connected Care, BD BioPharma Systems and BD Interventional. BD Medical Essentials segment includes medication delivery solutions and specimen management. BD Connected Care segment includes medication management solutions and advanced patient monitoring. BD Interventional segment includes urology and critical care, peripheral intervention and surgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
TCAF Stock Price Analysis and ETF Dynamics
- Price Fluctuation Analysis: TCAF's 52-week low is $28.28 and high is $39.34, with the latest trade at $35.78, indicating cautious market sentiment as the stock fluctuates within this range.
- Technical Analysis Tool: Comparing the latest stock price to the 200-day moving average provides valuable insights for investors, aiding in the assessment of price trends and potential buy or sell opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting the underlying holdings of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding helps identify those experiencing significant inflows or outflows, providing timely insights into market dynamics and potential impacts on individual stocks.
See More
Trump Administration Proposes Easing Ethylene Oxide Restrictions
- Policy Adjustment Context: The Trump administration is proposing to ease restrictions on ethylene oxide (EtO), a gas widely used for sterilizing medical devices like catheters and ventilators, in response to concerns from the medical community and federal agencies regarding current emission standards.
- Flexibility in New Standards: If finalized, the proposal would allow EtO commercial sterilization facilities to choose between installing a new monitoring system or complying with revised vent standards when emissions exceed ten tons per year, thereby enhancing facility flexibility to ensure effective sterilization of equipment.
- Economic Impact Assessment: The EPA estimates that this proposal could save $630 million over 20 years, or approximately $43 million annually, indicating the potential economic benefits of policy adjustments for the medical equipment supply chain.
- Public Participation Opportunity: A public hearing on the proposal is expected to occur 15 days after its publication in the Federal Register, with a 45-day period for public comments, highlighting the importance of transparency and public engagement in the policymaking process.
See More
Becton Dickinson Executive Affirms Ongoing Focus on Tuck-In M&A in High-Growth Sectors at Barclays Conference
- Company Strategy: Becton Dickinson's CEO has stated that the company will continue to pursue tuck-in mergers and acquisitions as part of its growth strategy.
- Focus Areas: The company is particularly focused on high-growth areas to enhance its market position and drive future success.
See More
Impressive Dividend Stocks in Healthcare Sector
- Becton, Dickinson's Dividend King Status: Becton, Dickinson has increased its dividend for over 50 years, earning its place as a Dividend King; despite recent struggles, its new product pipeline is expected to drive recovery, and the current 2.4% yield attracts long-term investors.
- Growth Potential in Medical Devices: Medtronic is just a few years away from Dividend King status, boasting a 2.9% dividend yield that is even more appealing; although facing challenges, the company has just begun selling surgical robots in the U.S., which is anticipated to provide significant growth opportunities.
- Valuation Discrepancies: Medtronic's P/E ratio stands at 27x, compared to the 63x of surgical robotics leader Intuitive Surgical, suggesting that the market may reward Medtronic with a higher valuation due to its advancements in surgical robotics, reflecting the potential of its diversified business.
- Low Investment Threshold: Investors can buy 5 shares of Becton, Dickinson or 10 shares of Medtronic for just $1,000, making both stocks reliable dividend options that currently have catalysts that may spur higher market valuations.
See More
Dividend Potential of Becton, Dickinson and Medtronic in Healthcare Sector
- Becton's Dividend History: Becton, Dickinson has increased its dividend for over 50 years, achieving a 2.4% yield, making it a solid investment choice in the healthcare sector; despite recent underperformance, its new product pipeline is expected to drive future growth.
- Medtronic's Growth Potential: Medtronic is on the verge of becoming a Dividend King with a 2.9% yield, having just launched surgical robots in the U.S. market, which is anticipated to create significant growth opportunities, particularly in the high-valuation surgical robotics sector.
- Low Investment Threshold: Investors can buy 5 shares of Becton or 10 shares of Medtronic for just $1,000, making these stocks ideal for small investors, especially given the current bearish market sentiment.
- Market Reaction Expectations: Although Becton was not recommended by The Motley Fool as a top investment, its long-standing dividend record and upcoming new products may attract long-term investors, particularly against the backdrop of sustained demand in the medical device industry.
See More
BD Receives CE Mark for Revello™ Vascular Stent
- CE Mark Achievement: BD announced that its Revello™ vascular stent has received CE marking, representing a significant advancement in the treatment of atherosclerotic lesions in common and external iliac arteries, which is expected to enhance the company's competitive position in the European market significantly.
- Technological Innovation: The Revello™ stent combines the flexibility of a self-expanding nitinol stent with radial resistive strength tailored for iliac arteries, featuring an ultra-thin expanded polytetrafluoroethylene coating designed to keep arteries open while minimizing trauma to healthy vascular segments, thereby improving patient outcomes.
- Clinical Trial Support: The ongoing AGILITY clinical trial, led by Dr. Sean Lyden from the Cleveland Clinic, evaluates the performance of Revello™ in patients with peripheral artery disease, providing crucial data to support the clinical application of the stent and enhancing physician confidence in the product.
- Market Launch Strategy: The Revello™ stent will be launched in European countries that accept CE marking, while in the U.S., it remains an investigational device limited to research use, a market strategy that will help BD establish a strong product foundation in Europe and drive future sales growth.
See More
TCAF Stock Price Analysis and ETF Dynamics
- Price Fluctuation Analysis: TCAF's 52-week low is $28.28 and high is $39.34, with the latest trade at $35.78, indicating cautious market sentiment as the stock fluctuates within this range.
- Technical Analysis Tool: Comparing the latest stock price to the 200-day moving average provides valuable insights for investors, aiding in the assessment of price trends and potential buy or sell opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting the underlying holdings of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding helps identify those experiencing significant inflows or outflows, providing timely insights into market dynamics and potential impacts on individual stocks.
See More
Trump Administration Proposes Easing Ethylene Oxide Restrictions
- Policy Adjustment Context: The Trump administration is proposing to ease restrictions on ethylene oxide (EtO), a gas widely used for sterilizing medical devices like catheters and ventilators, in response to concerns from the medical community and federal agencies regarding current emission standards.
- Flexibility in New Standards: If finalized, the proposal would allow EtO commercial sterilization facilities to choose between installing a new monitoring system or complying with revised vent standards when emissions exceed ten tons per year, thereby enhancing facility flexibility to ensure effective sterilization of equipment.
- Economic Impact Assessment: The EPA estimates that this proposal could save $630 million over 20 years, or approximately $43 million annually, indicating the potential economic benefits of policy adjustments for the medical equipment supply chain.
- Public Participation Opportunity: A public hearing on the proposal is expected to occur 15 days after its publication in the Federal Register, with a 45-day period for public comments, highlighting the importance of transparency and public engagement in the policymaking process.
See More
Becton Dickinson Executive Affirms Ongoing Focus on Tuck-In M&A in High-Growth Sectors at Barclays Conference
- Company Strategy: Becton Dickinson's CEO has stated that the company will continue to pursue tuck-in mergers and acquisitions as part of its growth strategy.
- Focus Areas: The company is particularly focused on high-growth areas to enhance its market position and drive future success.
See More
Impressive Dividend Stocks in Healthcare Sector
- Becton, Dickinson's Dividend King Status: Becton, Dickinson has increased its dividend for over 50 years, earning its place as a Dividend King; despite recent struggles, its new product pipeline is expected to drive recovery, and the current 2.4% yield attracts long-term investors.
- Growth Potential in Medical Devices: Medtronic is just a few years away from Dividend King status, boasting a 2.9% dividend yield that is even more appealing; although facing challenges, the company has just begun selling surgical robots in the U.S., which is anticipated to provide significant growth opportunities.
- Valuation Discrepancies: Medtronic's P/E ratio stands at 27x, compared to the 63x of surgical robotics leader Intuitive Surgical, suggesting that the market may reward Medtronic with a higher valuation due to its advancements in surgical robotics, reflecting the potential of its diversified business.
- Low Investment Threshold: Investors can buy 5 shares of Becton, Dickinson or 10 shares of Medtronic for just $1,000, making both stocks reliable dividend options that currently have catalysts that may spur higher market valuations.
See More
Dividend Potential of Becton, Dickinson and Medtronic in Healthcare Sector
- Becton's Dividend History: Becton, Dickinson has increased its dividend for over 50 years, achieving a 2.4% yield, making it a solid investment choice in the healthcare sector; despite recent underperformance, its new product pipeline is expected to drive future growth.
- Medtronic's Growth Potential: Medtronic is on the verge of becoming a Dividend King with a 2.9% yield, having just launched surgical robots in the U.S. market, which is anticipated to create significant growth opportunities, particularly in the high-valuation surgical robotics sector.
- Low Investment Threshold: Investors can buy 5 shares of Becton or 10 shares of Medtronic for just $1,000, making these stocks ideal for small investors, especially given the current bearish market sentiment.
- Market Reaction Expectations: Although Becton was not recommended by The Motley Fool as a top investment, its long-standing dividend record and upcoming new products may attract long-term investors, particularly against the backdrop of sustained demand in the medical device industry.
See More
BD Receives CE Mark for Revello™ Vascular Stent
- CE Mark Achievement: BD announced that its Revello™ vascular stent has received CE marking, representing a significant advancement in the treatment of atherosclerotic lesions in common and external iliac arteries, which is expected to enhance the company's competitive position in the European market significantly.
- Technological Innovation: The Revello™ stent combines the flexibility of a self-expanding nitinol stent with radial resistive strength tailored for iliac arteries, featuring an ultra-thin expanded polytetrafluoroethylene coating designed to keep arteries open while minimizing trauma to healthy vascular segments, thereby improving patient outcomes.
- Clinical Trial Support: The ongoing AGILITY clinical trial, led by Dr. Sean Lyden from the Cleveland Clinic, evaluates the performance of Revello™ in patients with peripheral artery disease, providing crucial data to support the clinical application of the stent and enhancing physician confidence in the product.
- Market Launch Strategy: The Revello™ stent will be launched in European countries that accept CE marking, while in the U.S., it remains an investigational device limited to research use, a market strategy that will help BD establish a strong product foundation in Europe and drive future sales growth.
See More
